Leading Microbiome Platform AMILI is the top precision gut microbiome company in Southeast Asia, with the largest multi-ethnic Asian gut microbiome database, positioning it as a key player in personalized health solutions and microbiome science.

Strategic Partnerships Recent collaborations with Cordlife and partnerships with healthcare providers highlight opportunities to expand microbiome banking and clinical services, creating avenues for selling advanced microbiome testing and banking solutions.

Strong Funding Momentum The company's US$10.5 million Series A funding and recent investments from East Ventures indicate solid financial backing, enabling expansion into new markets and the development of innovative microbiome-based health products.

Market Expansion Opportunities With active growth initiatives in Southeast Asia and Greater Asia, there is potential to introduce microbiome testing services, health data analytics, and personalized treatment plans to healthcare providers and wellness brands.

Technology-Driven Approach Utilizing cloud infrastructure like AWS and advanced web technologies, AMILI demonstrates a scalable platform suitable for integration with digital health solutions, data analytics tools, and remote health monitoring services.